Biotech company Geron has been plagued with problems lately. The company stopped its stem cell program last year in favor of developing cancer drugs. Recently, however, the company changed its strategy again; this time it canceled the development of cancer drug GRN1005 and has decided to focus entirely on the development of imetelstat -- which is now the only clinical candidate Geron has. Investors are wondering whether the company's new direction will work out.
Today, however, may have given investors some hope. Shares of this biotech jumped 16% after the company reported positive results from an imetelstat study at the American Society of Hematology meeting. Health care analyst Max Macaluso breaks down this news in the following video.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Is Geron's Latest Strategy Good News for Investors? originally appeared on Fool.com.Brenton Flynn, Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.